Paul Ken Leong Chin1,2, Philip George Drennan2, Sharon Jane Gardiner3, Mei Zhang4, Simon Charles Dalton5, Stephen Thomas Chambers1, Evan James Begg1. 1. Department of Medicine, University of Otago, Christchurch, New Zealand. 2. Department of Clinical Pharmacology, Canterbury District Health Board, Christchurch, New Zealand. 3. Antimicrobial Pharmacist, Departments of Clinical Pharmacology, Infectious Diseases and Pharmacy, Christchurch Hospital, Christchurch, New Zealand. 4. Department of Medicine, University of Otago, Christchurch, and Toxicology, Canterbury Health Laboratories, Christchurch, New Zealand. 5. Department of Infectious Diseases, Christchurch Hospital, Christchurch, New Zealand.
Abstract
AIMS: Flucloxacillin dosing may be guided by measurement of its total plasma concentrations. Flucloxacillin is highly protein bound with fraction unbound in plasma (fu ) of around 0.04 in healthy individuals. The utility of measuring unbound flucloxacillin concentrations for patients outside the intensive care unit (ICU) is not established. We aimed to compare flucloxacillin fu in non-ICU hospitalised patients against healthy volunteers, and to examine the performance of a published model for predicting unbound concentrations, using total flucloxacillin and plasma albumin concentrations. METHODS: Data from 12 healthy volunteers (248 samples) and 47 hospitalized patients (61 samples) were examined. Plasma flucloxacillin concentrations were measured using a validated liquid chromatography-tandem mass spectrometry method. Flucloxacillin fu for the two groups was compared using a generalized estimating equation model to account for clustered observations. The performance of the single protein binding site prediction model in hospitalized patients was compared with measured unbound concentrations using Bland-Altman plots. RESULTS: The median (range) flucloxacillin fu for healthy (median albumin 45 g l-1 ) and hospitalized individuals (median albumin 30 g l-1 ) were 0.04 (0.02-0.07) and 0.10 (0.05-0.37), respectively (P < 0.0001). The prediction model underpredicted unbound flucloxacillin concentrations with a mean bias (95% limits of agreement) of -54% (-137%, +30%). CONCLUSIONS: The flucloxacillin fu values observed in our cohort of hospitalized patients had a wide range and were greater than those of healthy individuals. Unbound flucloxacillin plasma concentrations were predicted poorly by the model. Instead, unbound concentrations should be measured to guide dosing.
AIMS: Flucloxacillin dosing may be guided by measurement of its total plasma concentrations. Flucloxacillin is highly protein bound with fraction unbound in plasma (fu ) of around 0.04 in healthy individuals. The utility of measuring unbound flucloxacillin concentrations for patients outside the intensive care unit (ICU) is not established. We aimed to compare flucloxacillin fu in non-ICU hospitalised patients against healthy volunteers, and to examine the performance of a published model for predicting unbound concentrations, using total flucloxacillin and plasma albumin concentrations. METHODS: Data from 12 healthy volunteers (248 samples) and 47 hospitalized patients (61 samples) were examined. Plasma flucloxacillin concentrations were measured using a validated liquid chromatography-tandem mass spectrometry method. Flucloxacillin fu for the two groups was compared using a generalized estimating equation model to account for clustered observations. The performance of the single protein binding site prediction model in hospitalized patients was compared with measured unbound concentrations using Bland-Altman plots. RESULTS: The median (range) flucloxacillin fu for healthy (median albumin 45 g l-1 ) and hospitalized individuals (median albumin 30 g l-1 ) were 0.04 (0.02-0.07) and 0.10 (0.05-0.37), respectively (P < 0.0001). The prediction model underpredicted unbound flucloxacillin concentrations with a mean bias (95% limits of agreement) of -54% (-137%, +30%). CONCLUSIONS: The flucloxacillin fu values observed in our cohort of hospitalized patients had a wide range and were greater than those of healthy individuals. Unbound flucloxacillin plasma concentrations were predicted poorly by the model. Instead, unbound concentrations should be measured to guide dosing.
Authors: Gloria Wong; Alexander Brinkman; Russell J Benefield; Mieke Carlier; Jan J De Waele; Najoua El Helali; Otto Frey; Stephan Harbarth; Angela Huttner; Brett McWhinney; Benoit Misset; Federico Pea; Judit Preisenberger; Michael S Roberts; Thomas A Robertson; Anka Roehr; Fekade Bruck Sime; Fabio Silvio Taccone; Jacobus P J Ungerer; Jeffrey Lipman; Jason A Roberts Journal: J Antimicrob Chemother Date: 2014-01-16 Impact factor: 5.790
Authors: John D Turnidge; Despina Kotsanas; Wendy Munckhof; Sally Roberts; Catherine M Bennett; Graeme R Nimmo; Geoffrey W Coombs; Ronan J Murray; Benjamin Howden; Paul D R Johnson; Kate Dowling Journal: Med J Aust Date: 2009-10-05 Impact factor: 7.738
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Paul Ken Leong Chin; Philip George Drennan; Sharon Jane Gardiner; Mei Zhang; Simon Charles Dalton; Stephen Thomas Chambers; Evan James Begg Journal: Br J Clin Pharmacol Date: 2018-07-20 Impact factor: 4.335
Authors: Eveline E Roelofsen; Brenda C M de Winter; Heleen van der Spek; Susan Snijders; Birgit C P Koch; Sanne van den Berg; Anouk E Muller Journal: Antibiotics (Basel) Date: 2022-08-03